Mutations in the gene encoding ubiquilin2 (UBQLN2) cause amyotrophic lateral sclerosis (ALS), frontotemporal type of dementia, or both. However, the molecular mechanisms are unknown. Here, we show that ALS/dementia-linked UBQLN2 P497H transgenic mice develop neuronal pathology with ubiquilin2/ubiquitin/p62-positive inclusions in the brain, especially in the hippocampus, recapitulating several key pathological features of dementia observed in human patients with UBQLN2 mutations. A major feature of the ubiquilin2-related pathology in these mice, and reminiscent of human disease, is a dendritic spinopathy with protein aggregation in the dendritic spines and an associated decrease in dendritic spine density and synaptic dysfunction. Finally, we show that the protein inclusions in the dendritic spines are composed of several components of the proteasome machinery, including Ub G76V -GFP, a representative ubiquitinated protein substrate that is accumulated in the transgenic mice. Our data, therefore, directly link impaired protein degradation to inclusion formation that is associated with synaptic dysfunction and cognitive deficits. These data imply a convergent molecular pathway involving synaptic protein recycling that may also be involved in other neurodegenerative disorders, with implications for development of widely applicable rational therapeutics.P rotein aggregates or inclusions with immunoreactivity to ubiquitin represent a common pathological hallmark in a broad range of late-onset neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson disease (PD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) (1). However, the molecular mechanisms underlying the formation of these inclusions and their relationship to neuronal dysfunction and degeneration are poorly understood. Mutations in UBQLN2, which encodes the ubiquitin-like protein ubiquilin2 (UBQLN2), have been recently shown to cause a subset of ALS, FTD-type of dementia, or both (2, 3). Notably, mutations within and in close proximity to the PXX domain of ubiquilin2 appear to have high penetrance as shown in familial cases (2). The distribution of ubiquilin2-positive inclusions in the brain and spinal cord is well correlated with cognitive and motor symptoms of patients with diverse etiology, including chromosome 9 open reading frame 72 (C9ORF72)-linked cases (2, 4). The ubiquilin2-positive inclusions appear to cover a wide range of protein inclusions, including those without TAR DNA binding protein (TDP43) immunoreactivity (2, 4), suggesting a primary role for ubiquilin2 in inclusion formation and neurodegeneration. Therefore, understanding the pathophysiological basis of UBQLN2-linked dementia may provide mechanistic insight into the pathogenesis of neurodegenerative disorders and allow for the design of rational therapies. To this end, we developed and characterized mutant UBQLN2 transgenic mice.
ResultsDevelopment of UBQLN2 P497H Transgenic Mice. Human UBQLN2 is an intronless gene. We analyzed the UBQLN2 promoter ...